However, the addition of the BRAF-inhibitor dabrafenib to a NRASQ61R/K/L mutant cancer cell, as investigated in our trial, might have paradoxically activated downstream signaling through RAF in the MAPK-pathway, which was possibly insufficiently inhibited by the downstream MEK-inhibitor trametinib in a subset of patients without any clinical benefit. This evidence concerns the gene BRAF and cancer.